..."/>

Boehringer Ingelheim Addresses Leucovorin Shortage

Boehringer Ingelheim, parent company of Bedford Laboratories, reports that Bedford is shipping some leucovorin, but that improvements in its manufacturing facilities will cause some short-term interruptions.

In a statement, Boehringer Ingleheim says that five lots of intravenous leucovorin were released between late November and mid-December, providing about 175,000 vials.  Another two lots are expect to be shipped before the end of 2008 containing another 167,000 vials.

According to the statement,

Bedford Laboratories will continue to work with the FDA drug shortage staff to provide updates on leucovorin.

Bedford Laboratories provides about half the leucovorin supply in the United States.  Boehringer Ingelheim is currently completing a new manufacturing facility in Bedford, Ohio as part of its  Ben Venue Laboratories / Bedford Laboratories subsidiary.

This unique 240,000 square foot, $140 million dedicated Cytotoxic/Genotoxic facility will serve our customers through the additional capacity it will provide and through offering state-of-the art technology and equipment in which to manufacture our products. Unfortunately, in the short-term, this is likely to cause some production interruptions. We anticipate resolution of these issues in the near future. Until such time, we will work diligently to fulfill our order commitments.

Recent leucovorin shortages have threatened colon and rectal cancer treatment and clinical trials that include 5-FU and leucovorin.   Shortages concern both oncologists and their patients.

Share on LinkedInShare on Google+Pin on PinterestTweet about this on TwitterShare on FacebookEmail this to someone

Related posts

*

*


4 + five =

Top